News

IPF Patients Being Recruited for Phase 2a Study of GLPG1690, an Oral Treatment

Galapagos NV recently announced the launch of an exploratory Phase 2a clinical trial, called FLORA, evaluating the company’s proprietary drug GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF). Esbriet (pirfenidone) and Ofev (nintedanib) are the only approved therapies for the treatment of IPF, and both have been shown…

Antegrin to Develop Oral Integrin Antagonists to Treat PF and Other Types of Fibrosis

Antegrin Therapeutics recently announced that it is expanding its current medication portfolio to include anti-fibrosis agents that block proteins known as integrins. The drugs were originally discovered at the Center for World Health & Medicine (CWHM) at Saint Louis University. Antegrin already offers several medications that target conditions characterized by fibrosis, including pulmonary…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums